Groundbreaking Research in Medicine Award Archives

🌱EARLY ACADEMIC PURSUITS

Dr. Wei Zheng embarked on his academic journey with a deep passion for medical sciences. He laid a strong foundation by specializing in nuclear medicine, focusing on the study and treatment of thyroid-related disorders. His early education was marked by a commitment to mastering both the theoretical and practical facets of his field, which later became the cornerstone of his distinguished career.

Currently, Dr. Wei Zheng serves as the Chief Physician and Deputy Director of the Department of Nuclear Medicine at Tianjin Medical University General Hospital. In addition to his clinical responsibilities, He mentors postgraduate students as a Master’s Supervisor. Dr. Zheng is actively involved in several prestigious organizations, including the Chinese Association of Medical Imaging Technology, the Chinese Association of Nuclear Medicine Physicians, and the Therapeutics Group of the Chinese Society of Nuclear Medicine, where he contributes to the advancement of nuclear medicine practices.

Dr. Zheng has made groundbreaking contributions in the diagnosis and treatment of thyroid-related disorders. His innovative work includes developing advanced therapies such as combining 131I with targeted drugs for iodine-refractory thyroid cancer and pioneering therapeutic strategies for Graves’ disease and ophthalmopathy. He has also spearheaded multicenter studies analyzing the effectiveness of 131I therapy in patients with lymph node and distant metastases, as well as in pediatric thyroid cancer cases. His research focuses on molecular imaging analysis using PET/MR and the pathogenesis of autoimmune thyroid disorders, aiming to advance both diagnosis and treatment.

Dr. Zheng’s research has profoundly influenced the field of nuclear medicine, particularly in the management and treatment of thyroid cancer and autoimmune thyroid diseases. His work has shaped clinical guidelines in China and expanded the global impact of radionuclide therapies. By integrating research findings into clinical practice, he has significantly improved patient outcomes and set a new standard for thyroid-related therapies.

With an h-index of 15 and 548 citations to his name, Dr. Zheng’s scholarly work is widely recognized and respected. His research papers, published in leading journals, have been frequently cited, reflecting his substantial contributions to the academic and medical communities. Over the past three years, he has authored 14 influential articles as a first or corresponding author, demonstrating his continued commitment to advancing scientific knowledge.

Dr. Zheng’s innovative approaches and groundbreaking research have left a lasting impact on nuclear medicine. His efforts have advanced the understanding and treatment of thyroid disorders and autoimmune diseases, paving the way for new therapeutic strategies. As he continues his work, he is dedicated to mentoring young researchers and contributing to global advancements in medical science, ensuring his legacy as a pioneer in his field.

Dr. Zheng is an active member and leader in numerous professional organizations. He serves as Director of the Chinese Association of Medical Imaging Technology, Vice Chairman of the Nuclear Medicine Branch of the Tianjin Association of Medical Imaging Technology, and a Standing Committee Member of the Chinese Association of Nuclear Medicine Physicians. Additionally, he holds editorial positions in esteemed journals, including the Chinese Journal of Nuclear Medicine and Molecular Imaging.

Dr. Zheng’s exceptional achievements have earned his a nomination for the Best Researcher Award under the China Scientist Awards. His ability to blend clinical expertise with innovative research underscores his standing as a leading figure in nuclear medicine, inspiring peers and setting new benchmarks in the field.

Optimization and application of renal depth measurement method in the cadmium-zinc-telluride‑based SPECT/CT renal dynamic imaging
- Authors: Zheng, H., Li, X., Wang, S., Jia, Q., Zheng, W.
- Journal: EJNMMI Physics, 2024, 11(1), 96
Selective anti-tumor activity of glutathione-responsive abasic site trapping agent in anaplastic thyroid carcinoma
- Authors: Chai, J., Su, M., Zhang, R., Sun, H., Meng, Z.
- Journal: BMC Cancer, 2024, 24(1), 816
Correction to: Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
- Authors: Yin, X., Lu, C., Sun, D., Tan, J., Zheng, W.
- Journal: Endocrine, 2024, 86(2), pp. 863
Mouse model of Graves’ orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene
- Authors: Wu, R., Li, N., Wang, X., Wang, R., Zheng, W.
- Journal: Journal of Endocrinological Investigation, 2024, 47(10), pp. 2507–2519
Comparison of 131I therapeutic responses and clinical outcomes in patients with familial and sporadic differentiated thyroid cancer
- Authors: Ji, Y., Wang, X., Li, X., Tan, J., Zheng, W.
- Journal: Chinese Journal of Radiological Medicine and Protection, 2024, 44(6), pp. 531–536